De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient

Am J Transplant. 2016 Sep;16(9):2753-7. doi: 10.1111/ajt.13852. Epub 2016 Jun 7.

Abstract

Benefits of belatacept-based immunosuppressive regimens in human immunodeficiency virus (HIV)-positive renal transplant recipients include avoidance of drug interactions between calcineurin inhibitors and highly active antiretroviral agents and decreased likelihood or severity of nonimmune toxicities such as new-onset diabetes after transplant, hyperlipidemia and hypertension. We report a successful case of de novo belatacept at >18 mo from transplant in an HIV-positive black man aged 50 years who received his first transplant from a living related kidney donor. To our knowledge, this case is the first reported of belatacept use in an HIV-positive renal transplant recipient.

Keywords: clinical research/practice; fusion proteins and monoclonal antibodies: belatacept; immunosuppressant; immunosuppression/immune modulation; infection and infectious agents; kidney transplantation/nephrology; viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

Publication types

  • Case Reports

MeSH terms

  • Abatacept / therapeutic use*
  • Glomerular Filtration Rate
  • Graft Rejection / drug therapy*
  • Graft Rejection / epidemiology
  • Graft Survival / drug effects*
  • HIV Infections / surgery*
  • HIV Infections / virology
  • HIV Seropositivity
  • HIV-1 / isolation & purification
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Failure, Chronic / surgery*
  • Kidney Failure, Chronic / virology
  • Kidney Function Tests
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Prognosis
  • Transplant Recipients

Substances

  • Immunosuppressive Agents
  • Abatacept